臨床婦人科産科74巻3号

2020年04月発行

今月の臨床 徹底解説！ 卵巣がんの最新治療―複雑化する治療を整理する ここが知りたい最新の治療戦略《初回治療》

組織型を考慮した初回化学療法は推奨されるか？

著者： 村上幸祐¹

所属機関： ¹近畿大学医学部産科婦人科学教室

ページ範囲：P.374 - P.378

●組織型を考慮した初回化学療法は，現時点では推奨されない．

●併用療法や，腫瘍の特性に応じたレジメンの個別化など，今後のエビデンスの集積が待たれる．

参考文献

1）Ozols RF, et al : Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer : a Gynecologic Oncology Group study. J Clin Oncol 21 : 3194-3200, 2003

2）Copeland LJ, et al : Clinical trials of newer regimens for treating ovarian cancer : the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol 90 : S1-S7, 2003

3）Katsumata N, et al : Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer（JGOG 3016）: a randomised, controlled, open-label trial. Lancet Oncol 14 : 1020-1026, 2013

4）Pignata S, et al : Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer（MITO-7）: a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15 : 396-405, 2014

5）Burger RA, et al : Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365 : 2473-2483, 2011

6）Perren TJ, et al : A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365 : 2484-2496, 2011

7）Verhaak RG, et al : Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123 : 517-525, 2013

8）Konecny GE, et al : Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst 106 : dju249, 2014

9）Murakami R, et al : Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. Gynecol Oncol 141 : 49-56, 2016

10）Murakami R, et al : The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma : A survey of Japanese Gynecologic Oncology Group study（JGOG3016A1）．Gynecol Oncol 153 : 312-319, 2019

11）Moore K, et al : Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379 : 2495-2505, 2018

12）Ho CM, et al : Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 94 : 197-203, 2004

13）Takano M, et al : Clear cell carcinoma of the ovary : a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94 : 1369-1374, 2006

14）Utsunomiya H, et al : Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma : a multicenter trial. Int J Gynecol Cancer 16 : 52-56, 2006

15）Itamochi H, et al : Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 93 : 723-728, 2002

16）Sugiyama T, et al : Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma : JGOG3017/GCIG trial. J Clin Oncol 34 : 2881-2887, 2016

17）Hess V, et al : Mucinous epithelial ovarian cancer : a separate entity requiring specific treatment. J Clin Oncol 22 : 1040-1044, 2004

18）Shimada M, et al : Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 113 : 331-334, 2009

19）National Comprehensive Cancer Network. Ovarian Cancer（Version 1.2019）. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf

20）Gore M, et al : An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer（mEOC/GOG 0241）with long-term follow-up : and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol 153 : 541-548, 2019